229 related articles for article (PubMed ID: 31491432)
1. Creation of a long-acting rilpivirine prodrug nanoformulation.
Hilaire JR; Bade AN; Sillman B; Gautam N; Herskovitz J; Dyavar Shetty BL; Wojtkiewicz MS; Szlachetka A; Lamberty BG; Sravanam S; Fox HS; Alnouti Y; Dash PK; McMillan JM; Edagwa BJ; Gendelman HE
J Control Release; 2019 Oct; 311-312():201-211. PubMed ID: 31491432
[TBL] [Abstract][Full Text] [Related]
2. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.
Zhou T; Su H; Dash P; Lin Z; Dyavar Shetty BL; Kocher T; Szlachetka A; Lamberty B; Fox HS; Poluektova L; Gorantla S; McMillan J; Gautam N; Mosley RL; Alnouti Y; Edagwa B; Gendelman HE
Biomaterials; 2018 Jan; 151():53-65. PubMed ID: 29059541
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic testing of a first-generation cabotegravir prodrug in rhesus macaques.
McMillan J; Szlachetka A; Zhou T; Morsey B; Lamberty B; Callen S; Gautam N; Alnouti Y; Edagwa B; Gendelman HE; Fox HS
AIDS; 2019 Mar; 33(3):585-588. PubMed ID: 30289818
[TBL] [Abstract][Full Text] [Related]
4. Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues.
Kevadiya BD; Ottemann B; Mukadam IZ; Castellanos L; Sikora K; Hilaire JR; Machhi J; Herskovitz J; Soni D; Hasan M; Zhang W; Anandakumar S; Garrison J; McMillan J; Edagwa B; Mosley RL; Vachet RW; Gendelman HE
Theranostics; 2020; 10(2):630-656. PubMed ID: 31903142
[TBL] [Abstract][Full Text] [Related]
5. Rilpivirine long-acting for the prevention and treatment of HIV infection.
Ferretti F; Boffito M
Curr Opin HIV AIDS; 2018 Jul; 13(4):300-307. PubMed ID: 29794818
[TBL] [Abstract][Full Text] [Related]
6. Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine.
Patel P; Teichner P; Elliot E; Boffito M; Murray M; Polli JW; Baker M; Ford SL; Han K; Russu A; Crauwels H; D'Amico RD; Spreen WR; van Wyk J
Ther Adv Infect Dis; 2023; 10():20499361231214626. PubMed ID: 38107552
[TBL] [Abstract][Full Text] [Related]
7. Cabotegravir and rilpivirine for the treatment of HIV.
Rial-Crestelo D; Pinto-Martínez A; Pulido F
Expert Rev Anti Infect Ther; 2020 May; 18(5):393-404. PubMed ID: 32164474
[No Abstract] [Full Text] [Related]
8. Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities.
Ottemann BM; Helmink AJ; Zhang W; Mukadam I; Woldstad C; Hilaire JR; Liu Y; McMillan JM; Edagwa BJ; Mosley RL; Garrison JC; Kevadiya BD; Gendelman HE
Biomaterials; 2018 Dec; 185():174-193. PubMed ID: 30245386
[TBL] [Abstract][Full Text] [Related]
9. Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase.
Melody K; McBeth S; Kline C; Kashuba AD; Mellors JW; Ambrose Z
Antimicrob Agents Chemother; 2015 Dec; 59(12):7762-70. PubMed ID: 26438501
[TBL] [Abstract][Full Text] [Related]
10. Formulation and pharmacology of long-acting rilpivirine.
Williams PE; Crauwels HM; Basstanie ED
Curr Opin HIV AIDS; 2015 Jul; 10(4):233-8. PubMed ID: 26049947
[TBL] [Abstract][Full Text] [Related]
11. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
Chounta V; Overton ET; Mills A; Swindells S; Benn PD; Vanveggel S; van Solingen-Ristea R; Wang Y; Hudson KJ; Shaefer MS; Margolis DA; Smith KY; Spreen WR
Patient; 2021 Nov; 14(6):849-862. PubMed ID: 34056699
[TBL] [Abstract][Full Text] [Related]
12. A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV.
Cranston RD; Dezzutti CS; Siegel A; Engstrom J; Shetler C; Richardson-Harman N; Abebe KZ; Back D; Else L; Egan D; Khoo S; Egan JE; Stall R; Williams P; Brand RM; Parikh UM; McGowan I
AIDS Res Hum Retroviruses; 2019 Sep; 35(9):794-804. PubMed ID: 31146534
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers.
Verloes R; Deleu S; Niemeijer N; Crauwels H; Meyvisch P; Williams P
HIV Med; 2015 Sep; 16(8):477-84. PubMed ID: 25988676
[TBL] [Abstract][Full Text] [Related]
14. In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.
Rajoli RKR; Back DJ; Rannard S; Meyers CF; Flexner C; Owen A; Siccardi M
Clin Pharmacokinet; 2018 Feb; 57(2):255-266. PubMed ID: 28540638
[TBL] [Abstract][Full Text] [Related]
15. Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain.
Moreno S; Rivero A; Ventayol P; Falcó V; Torralba M; Schroeder M; Neches V; Vallejo-Aparicio LA; Mackenzie I; Turner M; Harrison C
Infect Dis Ther; 2023 Aug; 12(8):2039-2055. PubMed ID: 37452174
[TBL] [Abstract][Full Text] [Related]
16. Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment.
McGowan I; Dezzutti CS; Siegel A; Engstrom J; Nikiforov A; Duffill K; Shetler C; Richardson-Harman N; Abebe K; Back D; Else L; Egan D; Khoo S; Egan JE; Stall R; Williams PE; Rehman KK; Adler A; Brand RM; Chen B; Achilles S; Cranston RD
Lancet HIV; 2016 Dec; 3(12):e569-e578. PubMed ID: 27658864
[TBL] [Abstract][Full Text] [Related]
17. Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
Rizzardini G; Overton ET; Orkin C; Swindells S; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Girard PM; Oka S; Andrade-Villanueva JF; Richmond GJ; Baumgarten A; Masiá M; Latiff G; Griffith S; Harrington CM; Hudson KJ; St Clair M; Talarico CL; Patel P; Cutrell A; Van Eygen V; D'Amico R; Mrus JM; Wu S; Ford SL; Chow K; Roberts J; Wills A; Walters N; Vanveggel S; Van Solingen-Ristea R; Crauwels H; Smith KY; Spreen WR; Margolis DA
J Acquir Immune Defic Syndr; 2020 Dec; 85(4):498-506. PubMed ID: 33136751
[TBL] [Abstract][Full Text] [Related]
18. Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension.
Mc Crudden MTC; Larrañeta E; Clark A; Jarrahian C; Rein-Weston A; Lachau-Durand S; Niemeijer N; Williams P; Haeck C; McCarthy HO; Zehrung D; Donnelly RF
J Control Release; 2018 Dec; 292():119-129. PubMed ID: 30395897
[TBL] [Abstract][Full Text] [Related]
19. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
Orkin C; Oka S; Philibert P; Brinson C; Bassa A; Gusev D; Degen O; García JG; Morell EB; Tan DHS; D'Amico R; Dorey D; Griffith S; Thiagarajah S; St Clair M; Van Solingen-Ristea R; Crauwels H; Ford SL; Patel P; Chounta V; Vanveggel S; Cutrell A; Van Eygen V; Vandermeulen K; Margolis DA; Smith KY; Spreen WR
Lancet HIV; 2021 Apr; 8(4):e185-e196. PubMed ID: 33794181
[TBL] [Abstract][Full Text] [Related]
20. Development and characterization of a long-acting nanoformulated abacavir prodrug.
Singh D; McMillan J; Hilaire J; Gautam N; Palandri D; Alnouti Y; Gendelman HE; Edagwa B
Nanomedicine (Lond); 2016 Aug; 11(15):1913-27. PubMed ID: 27456759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
